NEWS
08
2026-10
Breaking News | Fondaparinux Sodium API Gains Marketing Authorization!
Newland Pharma has recently received approval from the National Medical Products Administration (NMPA) for its Fondaparinux Sodium API.
02
2026-10
Milan Awaits Us in October | Newland Pharmaceutical Welcomes You to CPHI Worldwide 2026
Whether you are seeking a trusted API and intermediate manufacturing partner or discussing a specific project, we invite you to visit Booth H3K98.
01
2026-10
Grand Celebration of the Nation, Joy Shared by All | The 77th Anniversary of the Founding of the People's Republic of China
Grand Celebration of the Nation, Joy Shared by All | The 77th Anniversary of the Founding of the People's Republic of China
21
2026-09
Newland Pharmaceutical Awarded CEP Certificate for Moxifloxacin Hydrochloride API
Recently, our company received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP Certificate) for Moxifloxacin Hydrochloride API, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
PRODUCTS

COMPANY PROFILE
We are one of the early domestic manufacturers
engaged in the research, development and production of L-4-Hydroxyphenylglycine and its derivatives. All technical and quality indicators of our products have reached international standards.

CORPORATE CULTURE
The company has established a scientific human
resource management system and a competitive compensation system. Focusing on internal equity, we give full play to the incentive function of salary and benefits.

COMPANY HONOR
The company is a National High-tech Enterprise, a
Key Enterprise under the support of the Ministry of Commerce, a Key Enterprise for the Export of High-tech Products in Henan Province, a Pilot Innovation Enterprise of Henan Province,